Abstract
The stereoselectivity of mouse skin metabolic activation to dihydrodiols of the strong carcinogen 5-methylchrysene (5-MeC) and the weak carcinogen 6-methylchrysene (6-MeC) was investigated. Synthetic 1, 2-dihydro-l, 2-dihydroxy-5-methylchrysene (5-MeC-1, 2-diol), 5-MeC-7, 8-diol, and 6-MeC-1, 2-diol were resolved into their R, R-and S, S-enantiomers by chiral stationary phase high performance liquid chromatography. The absolute configurations of the enantiomers were assigned by their circular dichroism spectra. Using these enantiomers as standards, the metabolism of 5-MeC and 6-MeC in vitro in rat and mouse liver and in vivo in mouse epidermis was investigated. Only the R, R-enantiomers of each dihydrodiol predominated (>90%). The dihydrodiol enantiomers were tested for tumor initiating activity on mouse skin. In each case, the R,R-dihydrodiol enantiomer was significantly more tumorigenic than the S,S-enantiomer. The most tumorigenic compound was 5-MeC-1 Radiol; it was significantly more active than either 5-MeC-7 R,8R-diol or 6-MeC-1R,2R-diol. The results of this study demonstrate that there is a high degree of stereoselectivity in the metabolic activation of 5-MeC and 6-MeC to proximate tumorigenic dihydrodiols in mouse skin. The bay region methyl group has no effect on the stereoselectivity of activation to 1,2-dihydrodiol metabolites in the chrysene system.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3613-3617 |
| Number of pages | 5 |
| Journal | Cancer Research |
| Volume | 47 |
| Issue number | 14 |
| State | Published - Jul 1987 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'High Stereoselectivity in Mouse Skin Metabolic Activation of Methylchrysenes to Tumorigenic Dihydrodiols'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver